Evidence
Alzheimers Dement. 2024 Feb 8. doi: 10.1002/alz.13708. Online ahead of print.
ABSTRACT
Alzheimer’s disease (AD) represents a growing global health challenge, necessitating accurate and reliable diagnostic methodologies for timely intervention and management. Immunoassays, specifically designed to detect biomarkers associated with AD pathology, have emerged as pivotal tools in diagnostic development. Understanding of the established protocols ensures assay sensitivity, specificity, and reproducibility, thereby enhancing the clinical utility of these diagnostic tools. Here, we explore the considerations in immunoassay development, focusing on phosphorylated tau217 assays. Ultimately, a clear understanding of immunoassay development is paramount in advancing the precision and reliability of AD diagnostics, contributing to early detection, improved patient outcomes, and advancements in therapeutic interventions.
PMID:38328965 | DOI:10.1002/alz.13708
Add to Google Keep
Post to X
Share on Linkedin
Estimated reading time: 2 minute(s)
Latest: Psychiatryai.com #RAISR4D
Cool Evidence: Engaging Young People and Students in Real-World Evidence ☀️
Real-Time Evidence Search [Psychiatry]
AI Research [Andisearch.com]
Analytical and clinical validation of Alzheimer’s disease blood biomarkers with a focus on plasma p-tau217
🌐 90 Days
VR Related Evidence Matrix
Evidence Blueprint
Analytical and clinical validation of Alzheimer’s disease blood biomarkers with a focus on plasma p-tau217
☊ AI-Driven Related Evidence Nodes
(recent articles with at least 5 words in title)
More Evidence
Analytical and clinical validation of Alzheimer’s disease blood biomarkers with a focus on plasma p-tau217
🌐 365 Days
VR Related Evidence Matrix
